| Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab (NCT01730677) | National Cancer Center, Korea | 2012-07-01 |
| Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer (NCT02790320) | Eisai Farmacêutica S.A. | 2012-06-01 |
| Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer (NCT01627704) | Assistance Publique - Hôpitaux de Paris | 2012-06-01 |
| Multi-peptide Vaccine With Basilixumab for Breast Cancer (NCT01660529) | Abramson Cancer Center at Penn Medicine | 2012-06-01 |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer (NCT01626222) | Novartis Pharmaceuticals | 2012-06-01 |
| Abraxane in Treatment of Metastatic Breast Cancer (NCT02555696) | Celgene | 2012-05-31 |
| Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients (NCT01658033) | Fudan University | 2012-05-01 |
| Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (NCT01862900) | Providence Health & Services | 2012-04-27 |
| Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer (NCT01528345) | Novartis Pharmaceuticals | 2012-04-01 |
| Non-interventional Study With Nab-Paclitaxel (Abraxane®) (NCT01689610) | iOMEDICO AG | 2012-04-01 |
| A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate (NCT01517802) | Janssen Research & Development, LLC | 2012-03-28 |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer (NCT01288092) | Novartis Pharmaceuticals | 2012-03-01 |
| Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) (NCT02001974) | Dompé Farmaceutici S.p.A | 2012-02-27 |
| Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (NCT01534455) | GBG Forschungs GmbH | 2012-02-01 |
| A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer (NCT01548534) | University Hospital, Tours | 2012-02-01 |
| Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines (NCT01555944) | Teva Pharma | 2012-02-01 |
| Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer (NCT01392586) | Jeroen Bosch Ziekenhuis | 2012-02-01 |
| Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer (NCT01506609) | AbbVie | 2012-01-23 |
| A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer (NCT00907959) | Bionovo | 2012-01-01 |
| Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors (NCT01482156) | Novartis Pharmaceuticals | 2012-01-01 |
| A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer (NCT01550848) | Fudan University | 2012-01-01 |
| A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) (NCT01655992) | Fudan University | 2012-01-01 |
| Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects (NCT01516307) | OBI Pharma, Inc | 2011-12-01 |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) (NCT01492101) | Nektar Therapeutics | 2011-12-01 |
| Clinical Trial of Comparative Study of GB221 Pharmacokinetics (NCT04175171) | Genor Biopharma Co., Ltd. | 2011-11-07 |
| Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) (NCT01512199) | Daiichi Sankyo | 2011-11-01 |
| Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer (NCT01477060) | Fondazione Michelangelo | 2011-11-01 |
| Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy (NCT01401959) | SCRI Development Innovations, LLC | 2011-09-23 |
| Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib (NCT01847599) | Centre Jean Perrin | 2011-09-06 |
| Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer (NCT01338831) | Novartis Pharmaceuticals | 2011-09-01 |
| A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer (NCT01310231) | Ozmosis Research Inc. | 2011-08-22 |
| Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases (NCT01421017) | NYU Langone Health | 2011-08-19 |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (NCT01231659) | Novartis Pharmaceuticals | 2011-08-09 |
| Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer (NCT01300962) | UNC Lineberger Comprehensive Cancer Center | 2011-08-01 |
| Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer (NCT01207102) | Duke University | 2011-08-01 |
| Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer (NCT01978977) | Hellenic Oncology Research Group | 2011-07-01 |
| Fresolimumab and Radiotherapy in Metastatic Breast Cancer (NCT01401062) | Weill Medical College of Cornell University | 2011-07-01 |
| Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany) (NCT01416558) | GBG Forschungs GmbH | 2011-07-01 |
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients (NCT01306942) | Spanish Breast Cancer Research Group | 2011-07-01 |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer (NCT01361945) | Texas Tech University Health Sciences Center, El Paso | 2011-07-01 |
| Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer (NCT01501669) | National Cancer Center, Korea | 2011-06-01 |
| Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer (NCT01326481) | Tracon Pharmaceuticals Inc. | 2011-06-01 |
| Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients (NCT01368107) | Centre Leon Berard | 2011-06-01 |
| Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis (NCT01373710) | Institut Curie | 2011-05-19 |
| Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites (NCT01377324) | University Medical Center Groningen | 2011-05-01 |
| Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC) (NCT01380808) | Fudan University | 2011-05-01 |
| A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (NCT01351597) | Korean Breast Cancer Study Group | 2011-04-01 |
| Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer (NCT01231802) | Adherex Technologies, Inc. | 2011-04-01 |
| Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer (NCT01322893) | Lund University Hospital | 2011-03-01 |
| High Resolution 3D Diffusion-weighted Breast MRI (NCT01315106) | Stanford University | 2011-03-01 |
| An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory (NCT01240421) | Eisai Inc. | 2011-03-01 |
| Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (NCT01307891) | University of Alabama at Birmingham | 2011-03-01 |
| Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer (NCT01240941) | Vanderbilt-Ingram Cancer Center | 2011-02-01 |
| Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer (NCT01283789) | University of Kansas Medical Center | 2011-02-01 |
| IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer (NCT01543126) | Fudan University | 2011-02-01 |
| Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer (NCT01282931) | Health Outcomes Solutions | 2011-01-01 |
| A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer (NCT01784120) | Gachon University Gil Medical Center | 2011-01-01 |
| Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (NCT01266213) | Samsung Medical Center | 2010-12-01 |
| A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer (NCT01256567) | Eli Lilly and Company | 2010-12-01 |
| Aerobic Training in Metastatic Breast Cancer (NCT01725633) | Memorial Sloan Kettering Cancer Center | 2010-12-01 |
| PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer (NCT01248494) | Vanderbilt-Ingram Cancer Center | 2010-11-01 |
| Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients (NCT01278810) | Chinese Academy of Medical Sciences | 2010-11-01 |
| Trastuzumab and Vinorelbine in Advanced Breast Cancer (NCT01185509) | Dana-Farber Cancer Institute | 2010-11-01 |
| 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (NCT01935492) | Borstkanker Onderzoek Groep | 2010-11-01 |
| Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer (NCT01498458) | GBG Forschungs GmbH | 2010-10-01 |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer (NCT01238029) | Sponsor GmbH | 2010-10-01 |
| A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients (NCT01161368) | Central European Cooperative Oncology Group | 2010-09-01 |
| Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients (NCT01334099) | University Health Network, Toronto | 2010-07-01 |
| Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment (NCT01320111) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-07-01 |
| Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers (NCT01360177) | Stanford University | 2010-07-01 |
| Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients (NCT01176669) | Fudan University | 2010-06-01 |
| Demonstrate Efficacy and Safety of Metastatic Breast Cancer (NCT01084876) | Celltrion | 2010-06-01 |
| A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer (NCT01149798) | Fudan University | 2010-06-01 |
| Triple Negative Breast Cancer Biomarker Study (NCT01111175) | US Oncology Research | 2010-05-01 |
| Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer (NCT01132664) | Novartis Pharmaceuticals | 2010-05-01 |
| A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer (NCT01120561) | Genentech, Inc. | 2010-05-01 |
| Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease (NCT01387295) | Dorte Nielsen | 2010-04-01 |
| Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer (NCT01387373) | Dorte Nielsen | 2010-04-01 |
| China CellSearch Study (NCT01116869) | Johnson & Johnson Medical, China | 2010-03-25 |
| Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer (NCT00905021) | Baylor Breast Care Center | 2010-03-01 |
| Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca (NCT01074814) | Translational Drug Development | 2010-03-01 |
| Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer (NCT01113970) | Alaunos Therapeutics | 2010-03-01 |
| Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer (NCT00983424) | Northwestern University | 2010-02-01 |
| Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies (NCT01045421) | Millennium Pharmaceuticals, Inc. | 2010-02-01 |
| Evaluate Safety, Efficacy and Pharmacokinetics (NCT01084863) | Celltrion | 2010-02-01 |
| CARE Initiative: Real-world Emulation of the PALOMA-2 Trial (NCT06607601) | Aetion, Inc. | 2010-02-01 |
| Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer (NCT01060514) | Northwestern University | 2010-02-01 |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer (NCT00894504) | SCRI Development Innovations, LLC | 2010-02-01 |
| A Confirmation Study of Eribulin in Combination With Capecitabine (NCT01323530) | Eisai Limited | 2010-01-26 |
| Ixabepilone + Carboplatin Metastatic Breast Cancer (NCT01075100) | US Oncology Research | 2010-01-01 |
| Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer (NCT01033032) | SCRI Development Innovations, LLC | 2009-12-01 |
| Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL) (NCT01029925) | Jonsson Comprehensive Cancer Center | 2009-12-01 |
| Treatment With Ribavirin for Patients With Metastatic Breast Cancer (NCT01056757) | Jewish General Hospital | 2009-12-01 |
| Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer (NCT01259505) | Tokyo Medical University | 2009-12-01 |
| Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer. (NCT01262469) | UNICANCER | 2009-12-01 |
| A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer (NCT01036113) | Enzon Pharmaceuticals, Inc. | 2009-11-01 |
| Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE) (NCT01956552) | Institut Curie | 2009-11-01 |
| Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases (NCT01004172) | Dana-Farber Cancer Institute | 2009-11-01 |
| Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring (NCT01053104) | University of Oxford | 2009-11-01 |
| Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (NCT01007942) | Novartis Pharmaceuticals | 2009-10-01 |